Stock Watch: Filling In The Blanks In Clinical Trial Result Announcements
Missing Details Should Prompt Suspicion
Executive Summary
If a clinical trial is positive, with safety and efficacy that trounces the competition, why be coy about the details?
You may also be interested in...
Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
Alnylam’s Patisiran ATTR-CM Opportunity Boosted By New APOLLO-B Data
Phase III results for Onpattro (patisiran) in ATTR cardiomyopathy pave a path to approval – though the competitive profile is in question – and foreshadow potential success for follow-on drug vutrisiran.
Stock Watch: Alnylam’s Date With The Competition
When a loss-making rare disease biotech company’s product takes on Pfizer in the same indication but without the benefit of superior data, pharmaceutical marketing lessons will be learnt.